EVT Innovate develops drug discovery programmes and assets, both internally or through academic collaborations. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.
LAB282 / LAB150 / LAB591 / LAB031 / LAB10x
| Programme | EVT201 |
| Therapeutic area/Indication | CNS - Insomnia |
| Partner | Jingxin |
| Status | Phase II |
| Programme | BAY1817080 |
| Therapeutic area/Indication | Chronic cough |
| Partner | Bayer |
| Status | Phase II |
| Programme | ND |
| Therapeutic area/Indication | Chronic cough |
| Partner | Bayer |
| Status | Phase II |
| Programme | CT7001 |
| Therapeutic area/Indication | Oncology |
| Partner | Carrick |
| Status | Phase II |
| Programme | EVT401 |
| Therapeutic area/Indication | Immunology & Inflammation |
| Partner | CONBA Group |
| Status | Phase I |
| Programme | ND |
| Therapeutic area/Indication | Women`s health - Endometriosis |
| Partner | Bayer |
| Status | Phase I |
| Programme | ND |
| Therapeutic area/Indication | Women`s health - Endometriosis |
| Partner | Bayer |
| Status | Phase I |
| Programme | ND |
| Therapeutic area/Indication | Women`s health - Endometriosis |
| Partner | Bayer |
| Status | Phase I |
| Programme | ND |
| Therapeutic area/Indication | Respiratory |
| Partner | Boehringer Ingelheim |
| Status | Phase I |
| Programme | ND |
| Therapeutic area/Indication | Oncology |
| Partner | Boehringer Ingelheim/Xynomic Pharmaceuticals |
| Status | Phase I |
| Programme | ND |
| Therapeutic area/Indication | CNS - Pain |
| Partner | Novartis |
| Status | Pre-clinical |
| Programme | Various |
| Therapeutic area/Indication | Women`s health - Endometriosis |
| Partner | Bayer |
| Status | Pre-clinical |
| Programme | ND |
| Therapeutic area/Indication | Immunology & Inflammation |
| Partner | Topas Therapeutics |
| Status | Pre-clinical |
| Programme | ND |
| Therapeutic area/Indication | Pain |
| Partner | Boehringer Ingelheim |
| Status | Pre-clinical |
| Programme | EVT801 |
| Therapeutic area/Indication | Oncology |
| Partner | Sanofi |
| Status | Pre-clinical |
| Programme | TargetImmuniT |
| Therapeutic area/Indication | Oncology - Immunotherapy |
| Partner | Sanofi/Apeiron |
| Status | Pre-clinical |
| Programme | ND |
| Therapeutic area/Indication | Oncology |
| Partner | Exscientia |
| Status | Pre-clinical + several discovery programmes |
| Programme | ND |
| Therapeutic area/Indication | Fibrosis |
| Partner | Galapagos |
| Status | Pre-clinical |
| Programme | Various |
| Therapeutic area/Indication | Anti-infectives |
| Partner | >5 programmes |
| Status | Pre-clinical |
| Programme | Various |
| Therapeutic area/Indication | CNS, Metabolic, Pain & Inflammation |
| Partner | >10 further programmes |
| Status | Pre-clinical |
| Programme | Various |
| Therapeutic area/Indication | Nephrology |
| Partner | Bayer |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Immunology & Inflammation |
| Partner | UCB |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Neurodegeneration |
| Partner | Celgene |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Oncology - solid tumours |
| Partner | Celgene |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Immunology & Inflammation - Tissue Fibrosis |
| Partner | Pfizer |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Metabolic - Diabetes |
| Partner | Sanofi |
| Status | Discovery |
| Programme | TargetPicV |
| Therapeutic area/Indication | Antiviral |
| Partner | Bayer/Haplogen |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | Dermatological diseases |
| Partner | Almirall |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | Oncology |
| Partner | Breakpoint Therapeutics |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | Anti-infectives |
| Partner | Forge Therapeutics |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | FSHD |
| Partner | Facio Therapies |
| Status | Discovery |
| Programme | INDY inhibitor |
| Therapeutic area/Indication | Metabolic |
| Partner | Eternygen |
| Status | Discovery |
| Programme | ND |
| Therapeutic area/Indication | Fibrotic disease |
| Partner | Fibrocor/Galapagos |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Various |
| Partner | LAB282 / LAB150 / LAB591 / LAB031 / LAB10x |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Anti-infectives |
| Partner | >5 programmes |
| Status | Discovery |
| Programme | Various |
| Therapeutic area/Indication | Internal: Oncology, CNS, Metabolic, Pain & Inflammtion, Immunology and Anti-invectives |
| Partner | >40 further programmes |
| Status | Discovery |